40620 Federal Register / Vol. 77, No. 132 / Tuesday, July 10, 2012 / Notices 

(5) Shall not be an HHS employee 

working on their applications or 

submissions during assigned duty 

hours. 

(6) Shall not be an employee of the 

Office of the National Coordinator 

(7) Federal grantees may not use 

Federal funds to develop COMPETES 

Act challenge applications unless 

consistent with the purpose of their 

grant award. 

(8) Federal contractors may not use 

Federal funds from a contract to develop 

COMPETES Act challenge applications 

or to fund efforts in support of a 

COMPETES Act challenge submission. 

All individual members of a team 

must meet the eligibility requirements. 

An individual or entity shall not be 

deemed ineligible because the 

individual or entity used Federal 

facilities or consulted with Federal 

employees during a competition if the 

facilities and employees are made 

available to all individuals and entities 

participating in the competition on an 

equitable basis. 

Registration Process for Participants 

1. During the Challenge Submission 

Period, visit http://YourRecord.

Challenge.gov and register (Registration 

is free) or log in with an existing 

ChallengePost account. After a 

Contestant signs up, a confirmation 

email will be sent to the email address 

provided. The Contestant must use the 

confirmation email to verify his or her 

email address. The registered Contestant 

will then be able to enter a Submission. 

2. On YourRecord.Challenge.gov, 

click ‘‘Accept this challenge’’ to register 

your interest in participating. This step 

ensures that you will receive important 

challenge updates. 

3. Create a video and ensure the 

following (please read the Official Rules 

on http://YourRecord.challenge.gov for 

complete requirements): 

a. Your video addresses questions 

such as: 

i. What prompted you to ask for 

access to your health record? 

ii. What did you find when you 

reviewed your health record? 

iii. How did you, or your health care 

provider, improve your quality of care 

or that of a loved one after gaining 

access to your health record? In other 

words, what was the benefit of being 

able to view what was in your record? 

iv. What did you, or your provider 

learn from accessing your health record? 

Was any information missing or 

incorrect? 

v. What kinds of things were you able 

to do with your record once you had 

access to it? Share it with other 

providers? Check to make sure the 

information was correct? What else? 

b. Your video gives a specific example 

(personal story, experience, testimonial, 

or thoughtful idea) of the benefits of 

having access to view your health 

record and the ability to review what is 

in your health record. 

c. Your video encourages viewers to 

visit www.HealthIT.gov and to ask their 

health care provider to see and get a 

copy of their medical record. 

d. Your video is no longer than 2 

minutes. 

4. Confirm that you have read and 

agreed to the Official Rules. A 

Contestant will be required to fill out 

the submission form on 

YourRecord.Challenge.gov and must 

provide: 

• The title of the Video; 

• A link to the Video on 

YouTube.com or Vimeo.com (the Video 

should be no longer than 2 minutes); 

• A text description of how you or a 

loved one benefitted from having access 

to your health record 

• A transcript of the words spoken or 

sung in the video; and 

• Uploaded consent forms for 

everyone who appears in the video 

regardless of age. 

All individuals that appear in a Video 

must complete and sign the Video 

Consent Form. If a minor appears in the 

Video, the minor’s parent/legal guardian 

must also sign the Video Consent Form. 

A Submission will not be considered 

complete and eligible to win prizes 

without a completed Video Consent 

Form being uploaded from all 

individuals that appear in the Video. All 

completed Video Consent Forms must 

include a handwritten signature, and be 

scanned, combined in to a single file 

(ZIP, PDF, or doc), and uploaded on the 

submission form on 

BloodPressure.Challenge.gov. 

Amount of the Prize 

Winner Prize Quantity 

First Prize ................. $3,000 1 

Second Prize ............ 2,000 1 

Third Prize ................ 1,000 1 

Honorable Mention ... 500 2 

Popular Choice 

Award .................... 700 1 

Basis Upon Which Winner Will Be 

Selected 

Submissions that meet category 

requirements will be evaluated by an 

internal panel of judges for Category 

Prizes based on the following criteria (to 

be equally weighted): 

1. Quality of the Story (Includes 

elements such as the authenticity and 

originality of your story and how you 

described getting a copy of your 

information and using it to improve 

your quality of care or the care of a 

loved one.) 

2. Potential Impact for motivating and 

inspiring others to access their health 

record (Includes whether the video is 

compelling, instructive, and easy to 

follow so that others can achieve similar 

benefits after gaining access to their 

health record.) 

The five (5) Contestants whose 

Submissions earn the highest overall score 

will win, the prize money as outlined in the 

chart. In the event of a tie, winners will be 

selected based on their score on the criteria 

described in (1) and then (2). If there is still 

a tie then the winner will be selected based 

on a vote by the judging panel. 

Authority: 15 U.S.C. 3719. 

Dated: June 28, 2012. 

Erin Poetter, 

Consumer e-Health Policy Analyst, Office of 

the National Coordinator for Health 

Information Technology (ONC), Office of the 

Secretary (OS). 

[FR Doc. 2012–16821 Filed 7–9–12; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

AHRQ Workgroups on ICD–10–CM/ 

PCS Conversion of Quality Indicators 

(QIs) — Extension Date for 

Nominations 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of date extension. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

nominations for members of 

approximately 10 multidisciplinary 

workgroups, to be convened by AHRQ’s 

contractor, on ICD–10–CM/PCS 

conversion of the AHRQ Quality 

Indicators (QIs). This notice was 

previously published on June 4, 2012 

(http://www.gpo.gov/fdsys/pkg/FR– 

2012–06–04/pdf/2012–13306.pdf). 

DATES: Please submit nominations on or 

before July 22, 2012. Self-nominations 

are welcome. Third-party nominations 

must indicate that the individual has 

been contacted and is willing to serve 

on the workgroup. Selected candidates 

will be notified no later than July 31, 

2012. 

ADDRESSES: Nominations can be sent in 

the form of a letter or email, preferably 

as an electronic file with an email 

attachment and should specifically 

address the submission criteria as noted 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 77, No. 132 / Tuesday, July 10, 2012 / Notices 40621 

below. Electronic submissions are 

strongly encouraged. Responses should 

be submitted to: Attn: John Bat, Agency 

for Healthcare Research and Quality, 

Center for Delivery, Organization and 

Markets, 540 Gaither Road, Room 5119, 

Rockville, MD 20850, Email: john.bott@

AHRQ.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: John 

Bott, Agency for Healthcare Research 

and Quality, Center for Delivery, 

Organization and Markets, 540 Gaither 

Road, Room 5119, Rockville, MD 20850, 

Email: john.bott@AHRQ.hhs.gov; Phone: 

(301) 427–1317; Fax: (301) 427–1430. 

SUPPLEMENTARY INFORMATION: These 

workgroups are being formed as part of 

a structured approach for converting the 

existing QI specifications from ICD–9– 

CM to ICD–10–CM/PCS, incorporating 

coding expertise, clinical expertise, and 

health services research/quality 

measurement expertise. The workgroups 

will evaluate the results of automated 

’code mapping’’ from ICD–9–CM to 

ICD–10–CM/PCS, providing input and 

advice regarding similarities and 

differences between ICD–9–CM and 

ICD–10–CM/PCS codes that are mapped 

to each other. This workgroup process 

will lead to recommendations regarding 

how the existing AHRQ QIs should be 

re-specified using ICD–10–CM/PCS 

codes, retaining the original clinical 

intent of each indicator while taking 

advantage of the greater specificity of 

ICD–10–CM/PCS to improve the 

indicator’s validity. Workgroup 

participation will be uncompensated. 

For additional information about the 

AHRQ QIs, please visit the AHRQ Web 

site at http://www.QUALITYindicators. 

AHRQ.gov. 

Specifically, each Workgroup on ICD– 

10–CM/PCS Conversion of Quality 

Indicators will consist of: 

—At least three individuals with 

relevant clinical expertise (e.g., 

cardiovascular disease, neurologic 

disease, orthopedic and 

musculoskeletal disease, obstetrics 

and gynecologic disease, surgery, 

critical care and pulmonary disease, 

diabetes and endocrine disease, 

infectious disease, neonatology and 

pediatric disease, miscellaneous) and 

at least two individuals with relevant 

coding expertise. 

—One or more individuals with field 

experience using AHRQ QI measures 

for assessing hospital performance. 

—One or more individuals with 

expertise in validating ICD–9–CM or 

ICD–10–CM/PCS codes using chart 

abstraction (to assess criterion 

validity), or otherwise assessing their 

accuracy and usefulness in 

identifying individuals with specific 

adverse outcomes. 

—One or more individuals with 

experience using data from the AHRQ 

Healthcare Cost and Utilization 

Project or similar data for the purpose 

of calculating AHRQ QIs. 

Submission Criteria 

To be considered for membership on 

a QI ICD–10–CM/PCS Conversion 

Workgroup, please send the following 

information for each nominee: 

1. A brief nomination letter 

highlighting experience and knowledge 

relevant to the development, 

refinement, or testing of quality 

measures based on ICD9–CM and/or 

ICD–10–CM/PCS coded data, and 

demonstrating familiarity with the 

AHRQ QIs and health care 

administrative data. (See selection 

criteria below.) The nominee’s clinical 

or coding profession and specialty, and 

the spectrum of his or her clinical or 

coding expertise, should be described. 

Please include full contact information 

of nominee: name, title, organization, 

mailing address, telephone and fax 

numbers, and email address. 

2. Curriculum vita (with citations to 

any pertinent publications related to 

quality measure specification, ICD–9– 

CM, or ICD–10–CM/PCS). 

3. Description of any financial 

interest, recent conduct, or current or 

planned commercial, non-commercial, 

institutional, intellectual, public 

service, or other activities pertinent to 

the potential scope of the workgroups, 

which could be perceived as influencing 

the workgroup’s process or 

recommendations. The objective is not 

to prevent nominees with potential 

conflicts of interest from serving on the 

panels, but to obtain such information 

so as to best inform the selection of 

workgroup members, and to help 

minimize such conflicts. 

Nominee Selection Criteria 

Nominees should have technical 

expertise in health care quality measure 

development, refinement, or 

application, and familiarity with the 

ICD–9–CM and ICD–10–CM/PCS code 

sets (especially insofar as they are used 

to specify quality measures). 

More specifically, each candidate will 

be evaluated using the following 

criteria: 

—Knowledge of health care quality 

measurement using administrative 

data in specific, relevant clinical 

domains (e.g., cardiovascular disease, 

neurologic disease, orthopedic and 

musculoskeletal disease, obstetrics 

and gynecologic disease, surgery, 

critical care and pulmonary disease, 

diabetes and endocrine disease, 

infectious disease, neonatology and 

pediatric disease, miscellaneous); 

—Peer-reviewed publications relevant 

to developing, refining, testing, or 

applying health care quality measures 

based on ICD-coded administrative 

data; 

—Other experience developing, 

refining, testing, or applying health 

care quality measures based on ICDcoded administrative data; 

—Expertise in ICD–9–CM and/or ICD– 

10–CM/PCS coding; 

—Expertise in hospital quality 

improvement, patient safety, and/or 

clinical documentation improvement; 

—Familiarity with the AHRQ Quality 

Indicators and their application; and, 

—Availability to participate in 

conference calls and provide written 

comments starting from late August 

through October 2012. 

Time Commitment 

In an effort to solicit expert input and 

recommendations on conversion of the 

AHRQ QIs from ICD–9–CM to ICD–10– 

CM/PCS, we are initiating a technical 

review process that will require 

participation in approximately three to 

five conference calls with some pre and 

post evaluation time (estimated at 13 

hours). Results from this process will 

influence the conversion of the AHRQ 

QI from ICD–9–CM to ICD–10–CM/PCS. 

Beginning in late August through 

October, selected nominees will be 

asked to participate in the following 

activities: 

Workgroup Activities 

1. Review the current ICD–9–CM 

specifications of AHRQ QIs within the 

workgroup’s clinical domain (e.g., 

cardiovascular disease, neurologic 

disease, orthopedic and musculoskeletal 

disease, obstetrics and gynecologic 

disease, surgery, critical care and 

pulmonary disease, diabetes and 

endocrine disease, infectious disease, 

neonatology and pediatric disease, 

miscellaneous), along with background 

documents justifying or explaining 

those specifications (about 1.5 hours). 

2. Participate in teleconference to 

explain the workgroup activities and 

processes, and to discuss current QI 

specifications and their justification (1.0 

hours). 

3. Review proposed mapping of ICD– 

9–CM to ICD–10–CM/PCS codes and 

identify relevant questions and concerns 

(about 3 hours). 

4. Participate in teleconference to 

discuss the proposed mappings, 

including relevant questions and 

concerns (1.5 hours). 

mstockstill on DSK4VPTVN1PROD with NOTICES

40622 Federal Register / Vol. 77, No. 132 / Tuesday, July 10, 2012 / Notices 

5. Following a structured process 

(e.g., modified Delphi), provide specific 

input to support or modify the proposed 

mappings (about 2.5 hours). 

6. Participate in teleconference to 

discuss areas of disagreement among 

workgroup members, and to achieve 

consensus when possible (1.5 hours). 

7. Following a structured process 

(e.g., modified Delphi), provide specific 

input to support or modify the proposed 

mappings, incorporating changes 

accepted in previous steps (about 1.0 

hour). 

8. Participate in final (optional) 

teleconference to review final 

recommendations and discuss 

contextual issues (1.0 hour). 

Please note that should additional 

conference calls be necessary, 

workgroup members are expected to 

make every effort to participate. The 

workgroups will conduct business by 

telephone, email, or other electronic 

means as needed. 

Background 

The AHRQ Quality Indicators (AHRQ 

QIs) are a unique set of measures of 

health care quality that make use of 

readily available hospital inpatient 

administrative data. The QIs have been 

used for various purposes. Some of 

these include tracking, hospital selfassessment, reporting of hospitalspecific quality or pay for performance. 

The AHRQ QIs are provider- and arealevel quality indicators and currently 

consist of four modules: the Prevention 

Quality Indicators (PQI), the Inpatient 

Quality Indicators, the Patient Safety 

Indicators (PSI), and the Pediatric 

Quality Indicators (PedQIs). AHRQ is 

committed to converting the QIs from 

ICD–9–CM to ICD–10–CM/PCS in an 

accurate and transparent manner, taking 

advantage of the additional specificity 

of ICD–10–CM/PCS to improve the 

validity and usefulness of the QIs, from 

October 2014 onward. 

Dated: July, 2, 2012. 

Carolyn M. Clancy, 

AHRQ Director. 

[FR Doc. 2012–16734 Filed 7–9–12; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Mine Safety and Health Research 

Advisory Committee, National Institute 

for Occupational Safety and Health 

(MSHRAC, NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting for the 

aforementioned committee: 

Times and Dates: 

8:30 a.m.–5:15 p.m., August 20, 2012 

8:30 a.m.–4:30 p.m., August 21, 2012 

Place: Hilton Garden Inn Pittsburgh/ 

Southpointe, 1000 Corporate Drive, 

Canonsburg, Pennsylvania 15317. Telephone: 

(724) 743–5000, Fax: (724) 743–5010. 

Status: Open to the public, limited only by 

the space available. The meeting room 

accommodates approximately 50 people. 

Purpose: This committee is charged with 

providing advice to the Secretary, 

Department of Health and Human Services; 

the Director, CDC; and the Director, NIOSH, 

on priorities in mine safety and health 

research, including grants and contracts for 

such research, 30 U.S.C. 812(b)(2), Section 

102(b)(2). 

Matters To Be Discussed: The meeting will 

focus on engineering noise controls, reducing 

coal dust exposures, reducing injuries 

through improved illumination, 

demographics survey of the mining industry, 

implementation of the National Academy of 

Science’s recommendations, oxygen supply 

partnership, safety culture, occupational 

health and safety management systems, 

preventing coal dust explosions, and 

reducing silica exposures. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Jeffery L. Kohler, Ph.D., Designated Federal 

Officer, MSHRAC, NIOSH, CDC, 626 

Cochrans Mill Road, Mailstop P05, 

Pittsburgh, Pennsylvania 15236, telephone 

(412) 386–5301, fax (412) 386–5300. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: July 2, 2012. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2012–16776 Filed 7–9–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–N–0001] 

Anti-Infective Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Anti-Infective 

Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on September 5, 2012, from 8 a.m. 

to 5 p.m. 

Location: FDA White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room 

(rm. 1503), Silver Spring, MD 20993– 

0002. Information regarding special 

accommodations due to a disability, 

visitor parking, and transportation may 

be accessed at: http://www.fda.gov/

AdvisoryCommittees/default.htm; under 

the heading ‘‘Resources for You,’’ click 

on ‘‘Public Meetings at the FDA White 

Oak Campus.’’ Please note that visitors 

to the White Oak Campus must enter 

through Building 1. 

Contact Person: Diane Goyette, Center 

for Drug Evaluation and Research, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, email: 

AIDAC@fda.hhs.gov, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area) to find out further 

information regarding FDA advisory 

committee information. A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

Agency’s Web site at http://www.fda.

gov/AdvisoryCommittees/default.htm 

and scroll down to the appropriate 

advisory committee meeting link, or call 

the appropriate advisory committee 

information line to learn about possible 

modifications before coming to the 

meeting. 

Agenda: The committee will discuss 

new drug application (NDA) 201688, 

mstockstill on DSK4VPTVN1PROD with NOTICES